MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 129.1 USD | +0.58% |
|
+5.88% | +29.77% |
| 05-15 | Merck to present new oncology data | CF |
| 05-14 | Investors need more than PPI to make up their minds |  |
Presentation Operator MessageOperator (Operator)Good morning, my name is Kevin, and welcome to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-05-31
- Bernstein Strategic Decisions Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
129.1
USD
Average target price
138.5
USD
Spread / Average Target
+7.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +50.47% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| -1.62% | 11.98B | |
| +24.01% | 12.1B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Transcript : Moderna, Inc., Q4 2022 Earnings Call, Feb 23, 2023
